Ritalin and other drugs given to patients diagnosed with attention deficit hyperactivity disorder have been taken into consideration in a voting performed by the Food and Drug Administration advisory panel. The drug has led to the deaths of 19 children and 6 adults who had taken the drugs. It has been said that it would be “inappropriate, unethical behavior” to not disclose that there is a definite uncertainty concerning the ADHD drugs circulating among patients. The advisory panel has also recommended the inclusion of a medication guide with the drugs. While the FDA does not have to act on the advice of its advisory committees, it generally does, so expect some action concerning these harmful ADHD drugs in the future.
If a defective product has injured you or someone you know, try contacting Pomerantz, Perlberger, and Lewis of Philadelphia, Pennsylvania.
